Company / Operating Income
Travere Therapeutics, Inc. Operating Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$62.8M
FY2025
5-year range
-$388.1M / -$62.8M
FY2021-FY2025
Trend
+80.6%
vs FY2024
Sector context
#77 of 204
Health Care
What the data says
At -$63M, Travere Therapeutics, Inc.'s operating income ranks #77 of 204 in the Health Care sector. Operating Income has fluctuated over the past 10 years, ranging from -$388M in FY2023 to -$51M in FY2017.
Based on SEC 10-K filings.
-$63M in FY2025.
Improved from -$388M to -$63M over the past 2 years.
Health Care sector context is included.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#77 of 204 in Health CareTop 38% of 204This company -$62.8M Sector average $107.7M
▼
-158.3% below sector average
Key checks
Key Insights
- In FY2025, operating income increased 80.6% year-over-year.
- Ranks #77 out of 204 companies in the Health Care sector.
- Peak operating income was recorded in FY2017.
- Lowest operating income in the period was in FY2023.
Company context
Key Data Points
- Altman Z-Score -1.15 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$62.8M | +80.6% |
| FY2024 | -$323.8M | +16.6% |
| FY2023 | -$388.1M | -21.4% |
| FY2022 | -$319.8M | -132.8% |
| FY2021 | -$137.4M | -71.6% |
| FY2020 | -$80.0M | -48.8% |
| FY2019 | -$53.8M | +7.6% |
| FY2018 | -$58.2M | -14.7% |
| FY2017 | -$50.7M | +36.4% |
| FY2016 | -$79.8M | -57.3% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026